Neuralink

Neuralink

Overview

Neuralink is an American neurotechnology company founded in 2016 by Elon Musk, with headquarters in Fremont, California. The company develops implantable brain-computer interfaces (BCIs) and is focused on creating high-bandwidth neural interfaces to treat neurological conditions and ultimately achieve human-AI symbiosis[@neuralink].

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Fremont, California, USA |
| Founded | 2016 |
| Founder | Elon Musk |
| CEO | Elon Musk |
| Employees | ~300+ |
| Funding | ~80 million |

Technology

N1 Implant

Neuralink's flagship product is the N1 implantable brain-computer interface:

• Electrode Count: 1,024 electrodes across 64 threads
• Thread Diameter: 5 microns (human hair is ~75 microns)
• Wireless: Fully implantable, wireless data transmission
• Battery: Rechargeable inductive charging
• Size: Coin-sized implant

The Link

The Link is the subcutaneous receiver that:

• Processes neural signals from the electrode threads
• Wireless transmits data to external devices
• Recharges via inductive charging
• Contains the electronics for signal amplification and digitization

Surgical Robot

Neuralink developed a custom surgical robot (R1) to implant the threads:

• Precise insertion of micro-electrodes
• Avoids blood vessels during insertion
• Minimizes tissue damage
• Fully automated placement procedure

Clinical Trials

PRIME Study

Neuralink

Overview

Neuralink is an American neurotechnology company founded in 2016 by Elon Musk, with headquarters in Fremont, California. The company develops implantable brain-computer interfaces (BCIs) and is focused on creating high-bandwidth neural interfaces to treat neurological conditions and ultimately achieve human-AI symbiosis[@neuralink].

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Fremont, California, USA |
| Founded | 2016 |
| Founder | Elon Musk |
| CEO | Elon Musk |
| Employees | ~300+ |
| Funding | ~80 million |

Technology

N1 Implant

Neuralink's flagship product is the N1 implantable brain-computer interface:

• Electrode Count: 1,024 electrodes across 64 threads
• Thread Diameter: 5 microns (human hair is ~75 microns)
• Wireless: Fully implantable, wireless data transmission
• Battery: Rechargeable inductive charging
• Size: Coin-sized implant

The Link

The Link is the subcutaneous receiver that:

• Processes neural signals from the electrode threads
• Wireless transmits data to external devices
• Recharges via inductive charging
• Contains the electronics for signal amplification and digitization

Surgical Robot

Neuralink developed a custom surgical robot (R1) to implant the threads:

• Precise insertion of micro-electrodes
• Avoids blood vessels during insertion
• Minimizes tissue damage
• Fully automated placement procedure

Clinical Trials

PRIME Study

Neuralink's first-in-human clinical trial is called PRIME (Precise Robotically Implanted Brain-Computer Interface):

• Identifier: NCT05126784
• Status: Recruiting
• Target: Patients with quadriplegia due to spinal cord injury or ALS
• Primary Endpoint: Safety and device functionality

First Human Implant (2025)

In January 2025, Neuralink announced successful implantation of the N1 device in their first human patient:

• Patient demonstrated ability to control computer cursor using neural signals
• Successfully played chess and interacted with software
• Demonstrated high-accuracy motor intent decoding (>90%)
• No serious adverse events reported in initial cohort[@neuralink2025]

Second Patient

Neuralink has implanted devices in additional patients as part of the PRIME study, expanding clinical experience with the technology.

Applications

Initial Target Indications

Future Applications

• Human-AI Symbiosis: Musk's stated long-term goal is to enable humans to interface with AI
• Memory Augmentation: Potential for cognitive enhancement in Alzheimer's disease
• Treatment of Neurological Conditions: Depression, addiction, PTSD (speculative)

Competitive Landscape

Neuralink competes with other BCI companies:

| Company | Technology | Status |
|---------|------------|--------|
| Blackrock Neurotech | Utah Array | FDA Approved |
| Synchron | Stentrode | FDA IDE approved |
| Paradromics | High-density array | Clinical trials |
| Precision Neuroscience | Layer 7 array | Preclinical |

Regulatory Status

• FDA Breakthrough Device Designation: Granted for the N1 device
• FDA Approval for Human Trials: PRIME study approved
• Human Trials: Ongoing (2025-present)

Technical Advantages

Advantages over Competing Technologies

Challenges

Research Publications

Key Publications

Cross-References

Related Companies

• Blackrock Neurotech - Competing BCI company
• Synchron - Competing BCI company
• Paradromics - Competing BCI company

Related Pages

• Brain-Computer Interface Technology Landscape
• BCI Company Comparison Matrix
• [Motor Cortex](/brain-regions/motor-cortex)

Related Diseases

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Spinal Cord Injury](/diseases/spinal-cord-injury)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cell Types Overview](/companies/overview)
• [Gene Overview](/companies/overview)
• [Disease Overview](/companies/overview)

External Links

• [Neuralink Website](https://neuralink.com/)
• [PRIME Study Clinical Trial](https://clinicaltrials.gov/study/NCT05126784)
• [Neuralink Blog](https://neuralink.com/blog/)

References